Parabon receives NSF grant for prostate cancer therapeutic
RESTON, Va.óParabon NanoLabs Inc. recently announced the reception of a joint grant award from the National Science Foundation for a project with Janssen Research & Development LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The grant will support the companies in developing and testing PJ-01, a novel therapeutic for prostate cancer, which will be produced using Parabon's Essemblix Drug Development Platform. Financial details were not released, but the grant originated from the Technology Enhancement for Commercial Partnerships program.
"The NSF TECP program not only funds groundbreaking research, it also enables small business innovators to establish valuable industry relationships," Dr. Steven Armentrout, president and CEO of Parabon, said in a statement. "With intellectual partnership from Janssen's creative scientists, we are confident this project will further validate our Essemblix platform."